Compare Fox Corp Class A (FOXA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs TG Therapeutics Inc — how do they compare? Fox Corp Class A trades at $62.41 (market cap $25.36B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Fox Corp Class A is far larger — about 3.1× TG Therapeutics Inc's market cap, and Fox Corp Class A pays a 0.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and TG Therapeutics Inc for 16 Days on average.
| FOXA | TGTX | |
|---|---|---|
Market Cap | $25.36B | $8.16B |
Volume | 2,566,954 | 1,735,121 |
Sector | Media | Health |
52-Week High | $76.11 | $59.06 |
52-Week Low | $48.79 | $26.94 |
Typical Hold Time | 34 Days | 16 Days |
Enterprise Value | $28.72B | $8.37B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $63.57, up 1.39% today, with a bullish technical signal and strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate. The company's 2025 revenue grew to $16.3 billion, with a net income margin of 13.88%, while analyst consensus is bullish with a $72 price target. Key developments include the pending $22 billion Roku acquisition, currently under DOJ review, and insider buying by CEO Lachlan Murdoch.
The outlook for FOXA is positive, supported by earnings momentum, reasonable valuation (P/E 16.55), and strategic acquisitions. However, risks include regulatory scrutiny of the Roku deal and potential integration challenges. The stock offers upside to the consensus target but faces headline volatility from merger progress.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
